CoronaryAtlas logo
CoronaryAtlas
LPC (20:0)
Pathway / Myocardial injury (shared endpoint)

LPC (20:0)

lipid

Decreased LPC (20:0) content post-MI reflects phospholipid catabolism and myocardial dysfunction severity.

Pathway placement
Cascade stepMyocardial injury (shared endpoint)
Confidencemedium
RationaleDecreased lysophosphatidylcholine predicts heart-failure after MI; myocardial injury and remodeling marker.
Also acts inSystemic / off-pathway
Druggability
Not assessed (no mapped human gene target).

Type I vs non-Type I discrimination

ScoresLow-confidence (proxy)
R — rupture / Type-I
74
C — non-Type-I
77
A — assay feasibility
40
E — evidence strength
36
T1DI (composite)
7
Specificity differential (R−C)-3.8
Non-Type-I axis panel
Does this marker also move in each non-Type-I setting? mag 0–3; higher means less Type-I-specific. n/a = no evidence retrieved, which is not the same as no change.
No non-Type-I axis evidence retrieved.
Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.

Assay & specimen

Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum or plasma (EDTA to limit oxidation)
Collection tube
K2/K3-EDTA (lavender-top) · Serum separator (gold/red-top, SST)
Method / principle
LC-MS/MS lipidomics (targeted or shotgun)
Reagent / substrate
Deuterated lipid-class internal standards; MS/MS transitions
Platform
LC-MS/MS
Turnaround · availability
Research · Research-only

Literature evidence(1)